Valuation: Formycon AG

Capitalization 330M 383M 303M 286M 527M 37.1B 541M 3.61B 1.4B 17.46B 1.44B 1.41B 60.98B P/E ratio 2026 *
-17.8x
P/E ratio 2027 * 9.6x
Enterprise value 404M 469M 371M 350M 645M 45.4B 662M 4.42B 1.72B 21.37B 1.76B 1.72B 74.63B EV / Sales 2026 *
6.66x
EV / Sales 2027 * 2.93x
Free-Float
70%
Yield 2026 *
-
Yield 2027 * -
1 day-2.67%
1 week-0.66%
Current month+0.44%
1 month-4.21%
3 months-21.64%
6 months-21.97%
Current year-28.98%
1 week 18.18
Extreme 18.18
19.6
1 month 17.5
Extreme 17.5
20.1
Current year 15.8
Extreme 15.8
26.95
1 year 15.8
Extreme 15.8
31.3
3 years 15.8
Extreme 15.8
79.5
5 years 15.8
Extreme 15.8
94.1
10 years 14.65
Extreme 14.65
94.1
Manager TitleAgeSince
Chief Executive Officer - 2022-06-30
Director of Finance/CFO 57 2023-03-31
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 49 2020-12-09
Chairman 54 2024-06-11
Director/Board Member 54 2024-06-11
Change 5d. change 1-year change 3-years change Capi.($)
-2.78%-0.66%-20.44%-76.60% 385M
+4.21%+2.07%-15.01%-15.57% 41.61B
+1.01%-5.95%+26.98%+27.40% 32.58B
+1.61%+0.78%+267.79%+468.12% 30.69B
+0.50%-0.25%+21.66%-12.44% 28.84B
-0.38%-4.60%+23.25%+15.80% 25.65B
+0.17%+0.44% - - 14.76B
-0.31%+5.84%+201.07%+4,222.02% 13.74B
+1.74%-2.68%+116.87%+88.31% 11.98B
+2.03%+3.55%+9.70%+1.36% 12.3B
Average +0.79%-1.47%+70.21%+524.27% 21.26B
Weighted average by Cap. +1.43%-1.95%+70.63%+372.73%

Financials

2026 *2027 *
Net sales 60.76M 70.44M 55.66M 52.59M 96.96M 6.82B 99.4M 663M 258M 3.21B 264M 259M 11.21B 131M 152M 120M 114M 209M 14.74B 215M 1.43B 558M 6.94B 571M 559M 24.22B
Net income -18.59M -21.55M -17.03M -16.09M -29.66M -2.09B -30.41M -203M -79.02M -982M -80.87M -79.14M -3.43B 34.21M 39.66M 31.34M 29.61M 54.59M 3.84B 55.96M 373M 145M 1.81B 149M 146M 6.31B
Net Debt 73.99M 85.79M 67.78M 64.05M 118M 8.31B 121M 808M 315M 3.91B 322M 315M 13.65B 54.52M 63.22M 49.95M 47.2M 87.01M 6.12B 89.2M 595M 232M 2.88B 237M 232M 10.06B
Logo Formycon AG
Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
Employees
250
Date Price Change Volume
26-05-19 18.18 -2.78% 11,727
26-05-18 18.70 -0.95% 9,726
26-05-15 18.88 -0.63% 6,428
26-05-14 19.00 -0.84% 4,065
26-05-13 19.16 +4.70% 11,778
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.70EUR
Average target price
40.14EUR
Spread / Average Target
+114.67%

Quarterly revenue - Rate of surprise